PCNA and bone neoplasm: The assessment of the proliferative antigen expression yields predictive indicators in soft tissues and bone tumors, with several studies demonstrating the clinical value of anti-PCNA (proliferating cell nuclear antigen) and anti-p53 monoclonal antibodies in these tumors.